

GDP Select B Distillate

Sample ID: 2503APO1001.5607
Strain: GDP

Matrix: Concentrates & Extracts
Type: Formulated Vape Oil
Source Batch #:

Produced:
Collected: 03/06/2025 09:10 am
Received: 03/06/2025
Completed: 03/10/2025
Batch #: CAZ2504C-GDP-B
Harvest Date:

Client
Curaleaf, AZ
Lic. # 00000058ESFA63267513

Lot #:
Production/Manufacture Date:
Production/Manufacture Method: Multiple Solvents



Summary

Test	Date Tested	Result
Batch		Pass
Cannabinoids	03/07/2025	Complete
Residual Solvents	03/07/2025	Pass
Microbials	03/10/2025	Pass
Mycotoxins	03/07/2025	Pass
Pesticides	03/07/2025	Pass
Heavy Metals	03/06/2025	Pass

Cannabinoids by SOP-6

Complete

87.2181%	0.1781%	91.6043%	NT
Total THC	Total CBD	Total Cannabinoids ^(Q3)	Total Terpenes ^(Q3)

Analyte	LOD	LOQ	Result	Result	Q
	%	%	%	mg/g	
THCa		0.1000	ND	ND	
Δ9-THC		0.1000	87.2181	872.181	
Δ8-THC		0.1000	ND	ND	
THCV		0.1000	0.5018	5.018	
CBDa		0.1000	ND	ND	
CBD		0.1000	0.1781	1.781	
CBDVa		0.1000	ND	ND	
CBDV		0.1000	ND	ND	
CBN		0.1000	0.6817	6.817	
CBGa		0.1000	ND	ND	
CBG		0.1000	2.3864	23.864	
CBC		0.1000	0.6382	6.382	
Total THC			87.2181	872.1810	
Total CBD			0.1781	1.7810	
Total			91.6043	916.043	

Date Tested: 03/07/2025 07:00 am



Anthony Settanni
Anthony Settanni
Lab Director
03/10/2025

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child.

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.

GDP Select B Distillate

Sample ID: 2503APO1001.5607
Strain: GDP

Matrix: Concentrates & Extracts
Type: Formulated Vape Oil
Source Batch #:

Produced:
Collected: 03/06/2025 09:10 am
Received: 03/06/2025
Completed: 03/10/2025
Batch #: CAZ2504C-GDP-B
Harvest Date:

Client
Curaleaf, AZ
Lic. # 00000058ESFA63267513

Lot #:
Production/Manufacture Date:
Production/Manufacture Method: Multiple Solvents

Pesticides by SOP-22

Pass

Analyte	LOQ	Limit	Result	Q	Status	Analyte	LOQ	Limit	Result	Q	Status
	PPM	PPM	PPM				PPM	PPM	PPM		
Abamectin	0.2500	0.5000	ND		Pass	Hexythiazox	0.5000	1.0000	ND		Pass
Acephate	0.2000	0.4000	ND		Pass	Imazalil	0.1000	0.2000	ND		Pass
Acetamiprid	0.1000	0.2000	ND		Pass	Imidacloprid	0.2000	0.4000	ND		Pass
Aldicarb	0.2000	0.4000	ND		Pass	Kresoxim Methyl	0.2000	0.4000	ND		Pass
Azoxystrobin	0.1000	0.2000	ND		Pass	Malathion	0.1000	0.2000	ND		Pass
Bifenazate	0.1000	0.2000	ND		Pass	Metalaxyl	0.1000	0.2000	ND		Pass
Bifenthrin	0.1000	0.2000	ND		Pass	Methiocarb	0.1000	0.2000	ND		Pass
Boscalid	0.2000	0.4000	ND		Pass	Methomyl	0.2000	0.4000	ND		Pass
Carbaryl	0.1000	0.2000	ND		Pass	Myclobutanil	0.1000	0.2000	ND		Pass
Carbofuran	0.1000	0.2000	ND		Pass	Naled	0.2500	0.5000	ND		Pass
Chlorantraniliprole	0.1000	0.2000	ND		Pass	Oxamyl	0.5000	1.0000	ND		Pass
Chlorfenapyr	0.5000	1.0000	ND		Pass	Paclobutrazol	0.2000	0.4000	ND		Pass
Chlorpyrifos	0.1000	0.2000	ND		Pass	Permethrins	0.1000	0.2000	ND		Pass
Clofentezine	0.1000	0.2000	ND		Pass	Phosmet	0.1000	0.2000	ND		Pass
Cyfluthrin	0.5000	1.0000	ND		Pass	Piperonyl	1.0000	2.0000	ND		Pass
Cypermethrin	0.5000	1.0000	ND		Pass	Butoxide					
Daminozide	0.5000	1.0000	ND		Pass	Prallethrin	0.1000	0.2000	ND		Pass
Diazinon	0.1000	0.2000	ND		Pass	Propiconazole	0.2000	0.4000	ND		Pass
Dichlorvos	0.0500	0.1000	ND		Pass	Propoxur	0.1000	0.2000	ND		Pass
Dimethoate	0.1000	0.2000	ND		Pass	Pyrethrins	0.5000	1.0000	ND		Pass
Ethoprophos	0.1000	0.2000	ND		Pass	Pyridaben	0.1000	0.2000	ND		Pass
Etofenprox	0.2000	0.4000	ND		Pass	Spinosad	0.1000	0.2000	ND		Pass
Etoxazole	0.1000	0.2000	ND		Pass	Spiromesifen	0.1000	0.2000	ND		Pass
Fenoxycarb	0.1000	0.2000	ND		Pass	Spirotetramat	0.1000	0.2000	ND		Pass
Fenpyroximate	0.2000	0.4000	ND		Pass	Spiroxamine	0.2000	0.4000	ND		Pass
Fipronil	0.2000	0.4000	ND		Pass	Tebuconazole	0.2000	0.4000	ND		Pass
Flonicamid	0.5000	1.0000	ND		Pass	Thiacloprid	0.1000	0.2000	ND		Pass
Fludioxonil	0.2000	0.4000	ND		Pass	Thiamethoxam	0.1000	0.2000	ND		Pass
						Trifloxystrobin	0.1000	0.2000	ND		Pass

Date Tested: 03/07/2025 07:00 am



Anthony Settanni
Anthony Settanni
Lab Director
03/10/2025

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child.

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.

GDP Select B Distillate

Sample ID: 2503APO1001.5607
Strain: GDP

Matrix: Concentrates & Extracts
Type: Formulated Vape Oil
Source Batch #:

Produced:
Collected: 03/06/2025 09:10 am
Received: 03/06/2025
Completed: 03/10/2025
Batch #: CAZ2504C-GDP-B
Harvest Date:

Client
Curaleaf, AZ
Lic. # 00000058ESFA63267513

Lot #:
Production/Manufacture Date:
Production/Manufacture Method: Multiple Solvents

Microbials

Pass

Analyte	Limit	Result	Status	Q
Salmonella SPP by QPCR: SOP-15	Detected/Not Detected in 1g	ND	Pass	
Aspergillus Flavus Aspergillus Fumigatus or Aspergillus Niger by QPCR: SOP-14	Detected/Not Detected in 1g	ND	Pass	
Aspergillus Terreus by QPCR: SOP-14	Detected/Not Detected in 1g	ND	Pass	

Analyte	LOQ	Limit	Result	Status	Q
	CFU/g	CFU/g	CFU/g		
E. Coli by traditional plating: SOP-13	10.0	100.0	< 10 CFU/g	Pass	

Date Tested: 03/10/2025 12:00 am

Mycotoxins by SOP-22

Pass

Analyte	LOD	LOQ	Limit	Units	Status	Q
	µg/kg	µg/kg	µg/kg	µg/kg		
B1	5	10	20	ND	Pass	
B2	5	10	20	ND	Pass	
G1	5	10	20	ND	Pass	
G2	5	10	20	ND	Pass	
Total Aflatoxins	5	10	20	ND	Pass	
Ochratoxin A	5	10	20	ND	Pass	

Date Tested: 03/07/2025 07:00 am

Heavy Metals by SOP-21

Pass

Analyte	LOD	LOQ	Limit	Units	Status	Q
	PPM	PPM	PPM	PPM		
Arsenic	0.1000	0.1330	0.4000	ND	Pass	
Cadmium	0.1000	0.1330	0.4000	ND	Pass	
Lead	0.2500	0.3330	1.0000	ND	Pass	
Mercury	0.0500	0.0660	0.2000	ND	Pass	

Date Tested: 03/06/2025 07:00 am



Anthony Settanni
Anthony Settanni
Lab Director
03/10/2025

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child.

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.

GDP Select B Distillate

Sample ID: 2503APO1001.5607
Strain: GDP

Matrix: Concentrates & Extracts
Type: Formulated Vape Oil
Source Batch #:

Produced:
Collected: 03/06/2025 09:10 am
Received: 03/06/2025
Completed: 03/10/2025
Batch #: CAZ2504C-GDP-B
Harvest Date:

Client
Curaleaf, AZ
Lic. # 00000058ESFA63267513

Lot #:
Production/Manufacture Date:
Production/Manufacture Method: Multiple Solvents

Residual Solvents by SOP-3

Analyte	LOQ	Limit	Result	Status	Q
	PPM	PPM	PPM		Pass
Acetone	381.0000	1000.0000	ND	Pass	
Acetonitrile	154.0000	410.0000	ND	Pass	
Benzene	1.0000	2.0000	ND	Pass	
Butanes	1914.0000	5000.0000	ND	Pass	
Chloroform	24.0000	60.0000	ND	Pass	
Dichloromethane	231.0000	600.0000	ND	Pass	
Ethanol	1910.0000	5000.0000	ND	Pass	
Ethyl-Acetate	1907.0000	5000.0000	ND	Pass	
Ethyl-Ether	1901.0000	5000.0000	ND	Pass	
n-Heptane	1892.0000	5000.0000	ND	Pass	
Hexanes	115.0000	290.0000	ND	Pass	
Isopropanol	1915.0000	5000.0000	ND	Pass	
Isopropyl-Acetate	1908.0000	5000.0000	ND	Pass	
Methanol	1141.0000	3000.0000	ND	Pass	
Pentane	1923.0000	5000.0000	ND	Pass	
Toluene	343.0000	890.0000	ND	Pass	
Xylenes + Ethyl Benzene	841.0000	2170.0000	ND	Pass	

Date Tested: 03/07/2025 07:00 am



Anthony Settanni
Anthony Settanni
Lab Director
03/10/2025

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child;

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.

GDP Select B Distillate

Sample ID: 2503APO1001.5607
Strain: GDP

Matrix: Concentrates & Extracts
Type: Formulated Vape Oil
Source Batch #:

Produced:
Collected: 03/06/2025 09:10 am
Received: 03/06/2025
Completed: 03/10/2025
Batch #: CAZ2504C-GDP-B
Harvest Date:

Client
Curaleaf, AZ
Lic. # 00000058ESFA63267513

Lot #:
Production/Manufacture Date:
Production/Manufacture Method: Multiple Solvents

Terpenes

Analyte	LOQ	Result	Result	Q	Analyte	LOQ	Result	Result	Q
---------	-----	--------	--------	---	---------	-----	--------	--------	---



Primary Aromas

--	--	--	--	--

Date Tested:



Anthony Settanni

Anthony Settanni
Lab Director
03/10/2025

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child;
KEEP OUT OF REACH OF CHILDREN.
The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.

GDP Select B Distillate

Sample ID: 2503APO1001.5607
Strain: GDP

Matrix: Concentrates & Extracts
Type: Formulated Vape Oil
Source Batch #:

Produced:
Collected: 03/06/2025 09:10 am
Received: 03/06/2025
Completed: 03/10/2025
Batch #: CAZ2504C-GDP-B
Harvest Date:

Client
Curaleaf, AZ
Lic. # 00000058ESFA63267513

Lot #:
Production/Manufacture Date:
Production/Manufacture Method: Multiple Solvents

Qualifiers Definitions

Qualifier Notation	Qualifier Description
I1	The relative intensity of a characteristic ion in a sample analyte exceeded the acceptance criteria in subsection (L)(1) with respect to the reference spectra, indicating interference
L1	When testing for pesticides, fungicides, herbicides, growth regulators, heavy metals, or residual solvents, the percent recovery of a laboratory control sample is greater than the acceptance limits in subsection (K)(2)(c), but the sample's target analytes were not detected above the maximum allowable concentrations in Table 3.1 for the analytes in the sample
M1	The recovery from the matrix spike in subsection (K)(4) was: a. High, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
M2	The recovery from the matrix spike in subsection (K)(4) was: b. Low, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
M3	The recovery from the matrix spike in subsection (K)(4) was: c. Unusable because the analyte concentration was disproportionate to the spike level, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
R1	The relative percent difference for the laboratory control sample and duplicate exceeded the limit in subsection (K)(3), but the recovery in subsection (K)(2) was within acceptance criteria
V1	The recovery from continuing calibration verification standards exceeded the acceptance limits in subsection (J)(1)(b), but the sample's target analytes were not detected above the maximum allowable concentrations in Table 3.1 for the analytes in the sample
Q2	The sample is heterogeneous, and sample homogeneity could not be readily achieved using routine laboratory practices – Used to denote that the sample as-received could not be fully pre-homogenized in packaging prior to microbiology analysis
Q3	Testing result is for informational purposes only and cannot be used to satisfy dispensary testing requirements in R9-17-317.01(A) or labeling requirements in R9-17-317

Customer Supplied Information:

Notes and Addenda:



[Signature]

Bryant Kearl
Chief Scientific Officer
03/10/2025

Confident LIMS
All Rights Reserved
coa.support@confidentlims.com
(866) 506-5866
www.confidentlims.com



ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING:

Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens and can lead to an increased risk for cancer, tachycardia, hypertension, heart attack, and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn child. Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child;

KEEP OUT OF REACH OF CHILDREN.

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.